Abstract: [Problem] To provide, in place of injected agents (such as Vidaza® and Dacogen®) clinically used as therapeutic drugs for high-risk myelodysplastic syndromes, a medicine as a therapeutic drug or a prophylactic drug for various advanced solid tumors, said medicine having high stability with respect to cytidine deaminase which is a hydrolytic metabolic enzyme, being absorbed into the body even by oral administration, and having an effect of being integrated into a nucleic acid biosynthetic route and inhibiting DNA methyltransferases, i.e., DNMTs. [Solution] The aforementioned problem is solved by a novel compound represented by formula (I). (In the formula, R is a hydroxyl group or a hydrogen atom, and R1 and R2 are each a benzyl group that may have a substituent.

Abstract: [Problem] To provide, in place of injected agents (such as Vidaza® and Dacogen®) clinically used as therapeutic drugs for high-risk myelodysplastic syndromes, a medicine as a therapeutic drug or a prophylactic drug for various advanced solid tumors, said medicine having high stability with respect to cytidine deaminase which is a hydrolytic metabolic enzyme, being absorbed into the body even by oral administration, and having an effect of being integrated into a nucleic acid biosynthetic route and inhibiting DNA methyltransferases, i.e., DNMTs. [Solution] The aforementioned problem is solved by a novel compound represented by formula (I). (In the formula, R is a hydroxyl group or a hydrogen atom, and R1 and R2 are each a benzyl group that may have a substituent.

Abstract: A method for evaluation of a multi-component medicine by judging the degree of difference of the multi-component medicine to be evaluated from a group of multi-component medicines selected as a reference group by using a Mahalanobis distance obtained by combining the 3D-HPLC fingerprint data of a multi-component medicine with fingerprint data of 3D-HPLC of other multi-component medicines of the same kind forming a reference group, allocating variable axes in the MT method to the number of multi-component medicine and the elution time or detection wavelength of the fingerprint data, obtaining a unit space from the signal strength, and obtaining the Mahalanobis distance of the multi-component medicine from the unit space.

Abstract: A method for evaluation of a multi-component medicine comprising judging the degree of difference of the multi-component medicine to be evaluated from a group of multi-component medicines selected as a reference group by using a Mahalanobis distance obtained by a process comprising the following steps (1) to (8), (1) a step of obtaining fingerprint data of three-dimensional high performance liquid chromatography of the multi-component medicine to be evaluated, (2) a step of combining the fingerprint data obtained in (1) with fingerprint data of three-dimensional high performance liquid chromatography of other multi-component medicines of the same kind forming a reference group, (3) a step of allocating variable axes in the MT method to the number of multi-component medicine and either the elution time or detection wavelength of the fingerprint data of (2) above and regarding a signal strength as a characteristic amount in the MT method, (4) a step of obtaining a unit space from the characteristic amount of

Abstract: It is an object of the present invention to provide a demethylation method that, from among multiple methylated regions present in the genome DNA of a living cell, can demethylate a specified methylated region only without influencing the other methylated regions, and to achieve the object, a target methylated region present in either a sense or antisense DNA chain in genome DNA of a living cell is demethylated, by artificially generating in the living cell the following (a) RNA comprising a base sequence equivalent to the base sequence of a region comprising all or part of the target methylated region in the DNA chain where the target methylated region is present, or (b) RNA comprising a base sequence equivalent to the base sequence of a region comprising a region neighboring the target methylated region in the DNA chain where the target methylated region is present.

Abstract: &bgr;-Amino-&agr;-hydroxycarboxylic acid derivatives represented by the following formula and salts thereof which are useful as human immunodeficiency virus (HIV) protease inhibitors: The compounds are effective for treating a patient suffering from AIDS and AIDS related diseases.

Abstract: &bgr;-Amino-&agr;-hydroxycarboxylic acid derivatives represented by the following formula and salts thereof which are useful as human immunodeficiency virus (HIV) protease inhibitors: The compounds are effective for treating a patient suffering from AIDS and AIDS related diseases.